Sequential allogeneic HSCT after CAR-T therapy for relapsed/refractory acute lymphoblastic leukemia patients: A long-term follow-up result
Authors:
Open Access
- 11 February 2025
- journal article
- Published by Elsevier in Journal of Advanced Research
- Vol. 78, 461-469
Abstract
No abstract availableKeywords
Funding Information
- National Natural Science Foundation of China (82425002)
- National Natural Science Foundation of China (82200250)
- National Natural Science Foundation of China (82270234)
- National Natural Science Foundation of China (82370223)
- National Natural Science Foundation of China (82130003)
- Science and Technology Department of Zhejiang Province (2023C03060)
This publication has 27 references indexed in Scilit:
- CD19 chimeric antigen receptor-T cells as bridging therapy to allogeneic hematopoietic cell transplantation improves outcome in patients with refractory/relapsed B-cell acute lymphoblastic leukemiaHeliyon, 2024
- Prognostic factors impacting post-transplant outcomes in adult T-cell acute lymphoblastic leukemia: a registry-based study by the EBMT acute leukemia working partyBone Marrow Transplantation, 2024
- Prognostic factors and clinical outcomes in patients with relapsed acute leukemia after allogeneic hematopoietic stem cell transplantationBone Marrow Transplantation, 2023
- Clinical characteristics and outcomes of COVID-19 in haematopoietic stem-cell transplantation recipients: an observational cohort studyThe Lancet Haematology, 2021
- Allogeneic haematopoietic stem cell transplantation improves outcome of adults with relapsed/refractory Philadelphia chromosome-positive acute lymphoblastic leukemia entering remission following CD19 chimeric antigen receptor T cellsBone Marrow Transplantation, 2020
- Low toxicity and favorable overall survival in relapsed/refractory B-ALL following CAR T cells and CD34-selected T-cell depleted allogeneic hematopoietic cell transplantBone Marrow Transplantation, 2020
- Anti‐CD19 chimeric antigen receptor‐modified T‐cell therapy bridging to allogeneic hematopoietic stem cell transplantation for relapsed/refractory B‐cell acute lymphoblastic leukemia: An open‐label pragmatic clinical trialAmerican Journal of Hematology, 2019
- International, Multicenter Standardization of Acute Graft-versus-Host Disease Clinical Data Collection: A Report from the Mount Sinai Acute GVHD International ConsortiumTransplantation and Cellular Therapy, 2016
- Definition of GvHD-free, relapse-free survival for registry-based studies: an ALWP–EBMT analysis on patients with AML in remissionBone Marrow Transplantation, 2015
- National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group ReportTransplantation and Cellular Therapy, 2015